sorafenib has been researched along with Delayed Hypersensitivity in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Gu, YH; Qu, BQ; Song, R; Xu, Q; Zhao, W | 1 |
1 other study(ies) available for sorafenib and Delayed Hypersensitivity
Article | Year |
---|---|
Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation.
Topics: Amino Acid Sequence; Animals; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blood Cells; Blotting, Western; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Female; G1 Phase; Humans; Hypersensitivity, Delayed; Immunization; Interleukin-2; Interleukin-2 Receptor alpha Subunit; Lectins, C-Type; Lymphocyte Activation; Lymphocyte Specific Protein Tyrosine Kinase p56(lck); Male; MAP Kinase Kinase Kinases; Mice; Mice, Inbred BALB C; Molecular Sequence Data; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-raf; Pyridines; Receptors, Vascular Endothelial Growth Factor; Resting Phase, Cell Cycle; Sequence Homology, Amino Acid; Sorafenib; T-Lymphocytes | 2008 |